Pfizer Inc and BioNTech SE announced today that real-time data from Israel indicate that the two companies’ vaccine against Covid-19 he’s got 94% efficiency for preventing asymptomatic infections.
This means that the vaccine can greatly reduce the spread of the virus.
The companies also report that the latest analysis of Israeli data shows that The vaccine is 97% effective in preventing symptomatic infection, serious illness and death. These results confirm the data from Phase III of clinical trials of the vaccine in December, which showed 95% efficacy.
Data analysis also provided data on the efficacy of the B.1.1.7 highly contagious British variant of the virus. More than 80% of the samples examined when the analysis was performed belonged to this variant.
The number of cases of the South African variant (B.1.351) in Israel was very limited, so it was not possible to draw conclusions about the effectiveness of the vaccine against this variant, as reported by Reuters and relayed by the Athens News Agency.
According to real-time analysis of data from the Israeli vaccination campaign, unvaccinated individuals are 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die than those vaccinated with Covid-19. Pfizer / BioNTech vaccine.
Data were collected from January 17 to March 6. They have not yet been evaluated by peers.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
